{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:47Z","timestamp":1792723127950,"version":"4.5.0"},"reference-count":66,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One-third of patients with chronic spontaneous urticaria (CSU) require treatment beyond the licensed dose of omalizumab, but real-world data on response and predictors of updosed omalizumab remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated response rates to updosed omalizumab in patients with CSU with or without symptomatic dermographism and explored predictors of response to dosing at 450\u2005mg every 4 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 57 patients (27 with CSU, 30 with CSU and symptomatic dermographism) who were poorly responsive to or lost response to omalizumab at the licensed dose (300\u2005mg every 4 weeks). All received omalizumab 450\u2005mg every 4 weeks for \u2265 3\u2005months; selected patients were further escalated to 600\u2005mg. Disease control was assessed using the Urticaria Control Test (UCT), with scores \u2265 12 indicating well-controlled disease. Baseline clinical and laboratory characteristics were compared between responders and nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 72% of patients (41 of 57) achieved disease control with omalizumab 450\u2005mg over 6\u2005months. Among patients whose condition remained poorly controlled, 10 were escalated to 600\u2005mg, of whom 9 (90%) achieved disease control. Baseline UCT scores were higher in responders than nonresponders (9 vs. 7.5, P = 0.02). No significant differences were observed for age, body mass index, total IgE, anti-thyroid peroxidase levels or concomitant symptomatic dermographism. Low baseline IgE did not preclude the response to the updosed treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Omalizumab updosing to 450\u2005mg or 600\u2005mg every 4 weeks appears effective in patients with CSU with inadequate response to licensed dosing. Higher baseline UCT scores may predict better response, whereas conventional biomarkers of poor response seem less informative in updosed regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag411","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:19:03Z","timestamp":1789672743000},"source":"Crossref","is-referenced-by-count":0,"title":["Updosed omalizumab in chronic spontaneous urticaria with or without symptomatic dermographism"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-8229","authenticated-orcid":false,"given":"Muhammed Burak","family":"Y\u00fccel","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Kayseri City Education and Research Hospital , Kayseri ,","place":["Turkey"]},{"name":"Dermatology Clinic, Ergani State Hospital , Diyarbak\u0131r ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-6452","authenticated-orcid":false,"given":"Esranur","family":"\u00dcnal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ufuk University, Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1999-8837","authenticated-orcid":false,"given":"Mehmet","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Kayseri City Education and Research Hospital , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-2320","authenticated-orcid":false,"given":"Y\u0131lmaz","family":"Ula\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Kayseri City Education and Research Hospital , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9269-2619","authenticated-orcid":false,"given":"Rag\u0131p","family":"Erta\u015f","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Health Sciences, Kayseri City Education and Research Hospital , Kayseri ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8466-4351","authenticated-orcid":false,"given":"Clive E","family":"Grattan","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-6035","authenticated-orcid":false,"given":"Sinem","family":"Ornek Ozdemir","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]},{"name":"Department of Dermatology, University of Health Sciences, Ankara Training and Research Hospital , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026102222012537900_llag411-B1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/all.70210","article-title":"The international guideline for the definition, classification, diagnosis and management of urticaria","volume":"81","author":"Zuberbier","year":"2026","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/jdv.19637","article-title":"A comparative analysis of chronic inducible urticaria in 423 patients: clinical and laboratory features and comorbid conditions","volume":"38","author":"Ornek Ozdemir","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026102222012537900_llag411-B5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alit.2023.05.003","article-title":"Chronic urticaria and the pathogenic role of mast cells","volume":"72","author":"Elieh-Ali-Komi","year":"2023","journal-title":"Allergol Int"},{"key":"2026102222012537900_llag411-B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaci.2025.04.004","article-title":"Endotypes of chronic spontaneous urticaria and angioedema","volume":"156","author":"Wong","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B8","doi-asserted-by":"crossref","first-page":"109198","DOI":"10.1016\/j.intimp.2022.109198","article-title":"An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria","volume":"112","author":"Ornek","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2026102222012537900_llag411-B9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"175","author":"Guillen-Aguinaga","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026102222012537900_llag411-B10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"JAMA"},{"key":"2026102222012537900_llag411-B11","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"2026102222012537900_llag411-B12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B14","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1398-9995.2010.02409.x","article-title":"Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy","volume":"65","author":"Krause","year":"2010","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism \u2013 results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1159\/000536579","article-title":"Unveiling treatment response predictors in predominant subtypes of chronic inducible urticaria","volume":"185","author":"Ornek Ozdemir","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"2026102222012537900_llag411-B17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u2018real-world\u2019 evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026102222012537900_llag411-B18","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3346\/jkms.2022.37.e211","article-title":"Omalizumab on chronic spontaneous urticaria and chronic inducible urticaria: a real-world study of efficacy and predictors of treatment outcome","volume":"37","author":"Jeong","year":"2022","journal-title":"J Korean Med Sci"},{"key":"2026102222012537900_llag411-B19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026102222012537900_llag411-B20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/15569527.2021.1945618","article-title":"A patient-oriented approach to long-term use of omalizumab in chronic spontaneous urticaria","volume":"40","author":"Ornek","year":"2021","journal-title":"Cutan Ocul Toxicol"},{"key":"2026102222012537900_llag411-B21","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1111\/all.16256","article-title":"Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: a prospective multicentric observational study","volume":"79","author":"Pierrard","year":"2024","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000491530","article-title":"Omalizumab updosing for better disease control in chronic spontaneous urticaria patients","volume":"177","author":"Kocaturk","year":"2018","journal-title":"Int Arch Allergy Immunol"},{"key":"2026102222012537900_llag411-B23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jaip.2017.08.035","article-title":"Omalizumab for severe chronic spontaneous urticaria: real-life experiences of 280 patients","volume":"5","author":"Vadasz","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjd.16379","article-title":"Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria","volume":"179","author":"Curto-Barredo","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026102222012537900_llag411-B25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.abd.2022.03.003","article-title":"Omalizumab versus cyclosporine-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?","volume":"97","author":"Kocaturk","year":"2022","journal-title":"An Bras Dermatol"},{"key":"2026102222012537900_llag411-B26","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B27","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.jaip.2023.06.026","article-title":"The crucial role of IgE as a predictor of treatment response to omalizumab in chronic spontaneous urticaria","volume":"11","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B28","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000548107","article-title":"Low total IgE predicts non-response to omalizumab in chronic spontaneous urticaria: a 10-year real-life study","volume":"187","author":"Yegin Katran","year":"2026","journal-title":"Int Arch Allergy Immunol"},{"key":"2026102222012537900_llag411-B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2500\/aap.2019.40.4230","article-title":"Factors related to omalizumab resistance in chronic spontaneous urticaria","volume":"40","author":"Magen","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"2026102222012537900_llag411-B30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","article-title":"Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria","volume":"140","author":"Ertas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B31","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.23822\/EurAnnACI.1764-1489.147","article-title":"Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?","volume":"53","author":"Asero","year":"2021","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B34","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/cea.13066","article-title":"Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients","volume":"48","author":"Jorg","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2026102222012537900_llag411-B36","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil Fc\u03b5RI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2026102222012537900_llag411-B37","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jaci.2021.02.038","article-title":"The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes","volume":"147","author":"Johal","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/all.14033","article-title":"Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU","volume":"75","author":"Ertas","year":"2020","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B40","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/all.12901","article-title":"Definition, aims, and implementation of GA2LEN Urticaria Centers of Reference and Excellence","volume":"71","author":"Maurer","year":"2016","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B41","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.waojou.2018.11.007","article-title":"Validation of the Turkish version of the Urticaria Control Test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria","volume":"12","author":"Kocaturk","year":"2019","journal-title":"World Allergy Organ J"},{"key":"2026102222012537900_llag411-B42","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B44","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.jaip.2023.09.002","article-title":"Autoimmune diseases and low baseline IgE in chronic spontaneous urticaria: a clinical and therapeutic prospective analysis in real-life clinical practice","volume":"11","author":"Pesque","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B45","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.jacig.2024.100245","article-title":"Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: a real-world longitudinal study","volume":"3","author":"Lee","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026102222012537900_llag411-B46","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"2026102222012537900_llag411-B47","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune chronic spontaneous urticaria detection with IgG anti-TPO and total IgE","volume":"9","author":"Kolkhir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B48","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.waojou.2020.100501","article-title":"Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both","volume":"14","author":"Chen","year":"2021","journal-title":"World Allergy Organ J"},{"key":"2026102222012537900_llag411-B49","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1159\/000532021","article-title":"Anti-TPO IgG\/total IgE ratio: biomarker for omalizumab response prediction in chronic spontaneous urticaria","volume":"184","author":"Bras","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"2026102222012537900_llag411-B50","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jaip.2022.02.039","article-title":"Is anti-TPO IgG and total IgE clinically useful for the detection of autoimmune chronic spontaneous urticaria?","volume":"10","author":"Sanchez","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B51","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jaip.2023.02.006","article-title":"Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa","volume":"11","author":"Xiang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B52","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026102222012537900_llag411-B53","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026102222012537900_llag411-B54","doi-asserted-by":"crossref","first-page":"1451296","DOI":"10.3389\/falgy.2024.1451296","article-title":"IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria","volume":"5","author":"Ensina","year":"2025","journal-title":"Front Allergy"},{"key":"2026102222012537900_llag411-B55","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.20737","article-title":"Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria","volume":"39","author":"Zhang","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026102222012537900_llag411-B56","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/1203475419847956","article-title":"The real-life effectiveness and safety of omalizumab updosing in patients with chronic spontaneous urticaria","volume":"23","author":"Salman","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"2026102222012537900_llag411-B58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.4168\/aair.2019.11.1.29","article-title":"Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests","volume":"11","author":"Sanchez","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"2026102222012537900_llag411-B59","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.3390\/ijms24087491","article-title":"Thyroid autoimmunity in CSU: a potential marker of omalizumab response?","volume":"24","author":"Asero","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026102222012537900_llag411-B60","doi-asserted-by":"crossref","first-page":"e12975","DOI":"10.1111\/dth.12975","article-title":"The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: real-life data","volume":"32","author":"Salman","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026102222012537900_llag411-B61","doi-asserted-by":"crossref","first-page":"e2022148","DOI":"10.5826\/dpc.1204a148","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome","volume":"12","author":"Russo","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"2026102222012537900_llag411-B62","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.19312","article-title":"Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria","volume":"183","author":"Castagna","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026102222012537900_llag411-B63","doi-asserted-by":"crossref","first-page":"e15248","DOI":"10.1111\/dth.15248","article-title":"Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria","volume":"35","author":"Foti","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026102222012537900_llag411-B64","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102222012537900_llag411-B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2026.02.018","article-title":"Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria","author":"Metz","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"2026102222012537900_llag411-B66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag411\/71207958\/llag411.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag411\/71207958\/llag411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:01:38Z","timestamp":1792720898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag411\/8814958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag411","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"llag411"}}